Diabetes &
Primary Care

Issue:

Vol:25 | No:01

Share this article

↓ Download pdf

Need to know guide: SGLT2 inhibitors: Indications, doses and licences in adults

Pam Brown

A printable guide to SGLT2 inhibitors, organised by drug and by indication.

Save, Share, Print Article

Share this article

↓ Download pdf

In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.

Update history

19 October 2023: Updated to reflect changes in licensing for empagliflozin.

Need to know, Newer therapies

Diabetes &
Primary Care

Need to know guide: SGLT2 inhibitors: Indications, doses and licences in adults

Update history

Diabetes Distilled: Tirzepatide SURMOUNTs semaglutide for weight loss

Diabetes Distilled: Age and sex and glucose-lowering drug efficacy

Interactive case study: Diabetic kidney disease

Rolling out tirzepatide for weight management: NHS England recommendations

Diabetes Distilled: Heart and SOUL – oral semaglutide demonstrates cardiovascular benefit in high-risk people with type 2 diabetes

NICE overweight and obesity guidelines – what’s new?

PCDO Society National Conference 2025: Request for poster abstracts